2 Tokunaga S, Hashiguchi A, Yoshimura A, et al. Late-onset Charcot-Marie-Tooth disease 4F caused by periaxin gene mutation. Neurogenetics, 2012, 13: 359-365
[2]
3 Azzedine H, Senderek J, Rivolta C, et al. Molecular genetics of charcot-marie-tooth disease: from genes to genomes. Mol Syndromol, 2012, 3: 204-214
[3]
4 Boerkoel C F, Takashima H, Stankiewicz P, et al. Periaxin mutations cause recessive Dejerine-Sottas neuropathy. Am J Hum Genet, 2001, 68: 325-333
[4]
5 Patzig J, Jahn O, Tenzer S, et al. Quantitative and integrative proteome analysis of peripheral nerve myelin identifies novel myelin proteins and candidate neuropathy loci. J Neurosci, 2011, 31: 16369-16386
[5]
6 Williams A C, Brophy P J. The function of the Periaxin gene during nerve repair in a model of CMT4F. J Anat, 2002, 200: 323-330
[6]
7 Dytrych L, Sherman D L, Gillespie C S, et al. Two PDZ domain proteins encoded by the murine periaxin gene are the result of alternative intron retention and are differentially targeted in Schwann cells. J Biol Chem, 1998, 273: 5794-5800
[7]
8 Han H, Kursula P. Periaxin and AHNAK nucleoprotein 2 form intertwined homodimers through domain swapping. J Biol Chem, 2014, 289: 14121-14131
10 Shi Y, Zhang L, Yang T. Nuclear export of L-periaxin, mediated by its nuclear export signal in the PDZ domain. PLoS One, 2014, 9: e91953
[10]
11 Gillespie C S, Lee M, Fantes J F, et al. The gene encoding the Schwann cell protein periaxin localizes on mouse chromosome 7 (Prx). Genomics, 1997, 41: 297-298
[11]
12 Sherman D L, Brophy P J. A tripartite nuclear localization signal in the PDZ-domain protein L-periaxin. J Biol Chem, 2000, 275: 4537-4540
[12]
13 Sherman D L, Fabrizi C, Gillespie C S, et al. Specific disruption of a schwann cell dystrophin-related protein complex in a demyelinating neuropathy. Neuron, 2001, 30: 677-687
[13]
14 Sherman D L, Wu L M, Grove M, et al. Drp2 and periaxin form Cajal bands with dystroglycan but have distinct roles in Schwann cell growth. J Neurosci, 2012, 32: 9419-9428
[14]
15 Gillespie C S, Sherman D L, Fleetwood-Walker S M, et al. Peripheral demyelination and neuropathic pain behavior in periaxin-deficient mice. Neuron, 2000, 26: 523-531
[15]
16 Wu L M, Williams A, Delaney A, et al. Increasing internodal distance in myelinated nerves accelerates nerve conduction to a flat maximum. Curr Biol, 2012, 22: 1957-1961
[16]
17 Masaki T, Matsumura K. Biological role of dystroglycan in Schwann cell function and its implications in peripheral nervous system diseases. J Biomed Biotechnol, 2010, 2010: 740403
[17]
18 Nyfeler B, Michnick S W, Hauri H P. Capturing protein interactions in the secretory pathway of living cells. Proc Natl Acad Sci USA, 2005, 102: 6350-6355
[18]
19 Scherer S S, Xu Y T, Bannerman P G, et al. Periaxin expression in myelinating Schwann cells: modulation by axon-glial interactions and polarized localization during development. Development. 1995, 121: 4265-4273
21 Jin H, Tan S, Hermanowski J, et al. The dystrotelin, dystrophin and dystrobrevin superfamily: new paralogues and old isoforms. BMC Genomics, 2007, 8: 19
[21]
22 Djinovic-Carugo K, Gautel M, Ylanne J, et al. The spectrin repeat: a structural platform for cytoskeletal protein assemblies. FEBS Lett, 2002, 513: 119-123
[22]
23 Ipsaro J J, Huang L, Mondragon A. Structures of the spectrin-ankyrin interaction binding domains. Blood, 2009, 113: 5385-5393
[23]
24 Machnicka B, Czogalla A, Hryniewicz-Jankowska A, et al. Spectrins: a structural platform for stabilization and activation of membrane channels, receptors and transporters. Biochim Biophys Acta, 2014, 1838: 620-634
[24]
25 Metral S, Machnicka B, Bigot S, et al. AlphaII-spectrin is critical for cell adhesion and cell cycle. J Biol Chem, 2009, 284: 2409-2418
27 谭斯品, 肖献忠, Roberts Roland G. 运用酵母双杂交系统筛选肌营养不良相关蛋白2(DRP2)相互作用蛋白. 中国现代医学杂志, 2008, 18: 133-137
[27]
28 Kasuboski J M, Bader J R, Vaughan P S, et al. Zwint-1 is a novel Aurora B substrate required for the assembly of a dynein-binding platform on kinetochores. Mol Biol Cell, 2011, 22: 3318-3330
[28]
1 Pareyson D, Marchesi C. Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol, 2009, 8: 654-667
